An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria

Roche

Status: Completed

Conditions: Hepatitis C

Treatments: Drug: Ribavirin; Drug: Peginterferon alfa-2a

Study type: Observational

Funder types: Industry

Identifiers

NCT02515279

ML22273

Details and patient eligibility

About

This noninterventional, open-label study will observe the safety and tolerability of peginterferon alfa-2a in combination with ribavirin among Austrian participants treated for HCV infection according to routine practice.

Enrollment: 463 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ongoing treatment with peginterferon alfa-2a and ribavirin at the discretion of the prescribing physician
• HCV infection

Exclusion criteria

• None specified

Trial design

463 participants in 1 patient group

Participants With Hepatitis C

Description:

All participants were treated with Peginterferon alfa-2a+Ribavirin (Pegasys/Copegus) according to the summary of product characteristics and to the investigator's discretion. The daily recommended dose for Pegasys, for the treatment of chronic Hepatitis C, was 180 micrograms once weekly by subcutaneous administration. Copegus was administered orally in doses according to the physician's decision (depending on the participant's weight and genotype). All participants were observed for 12 months.

Treatment:

Drug: Peginterferon alfa-2a

Drug: Ribavirin